Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
Internal tandem duplications (ITDs) of the gene encoding the Fms-Like Tyrosine kinase-3 (FLT3) receptor are present in approximately 25% of patients with acute myeloid leukemia (AML). The mutation is associated with poor prognosis, and the aberrant protein product has been hypothesized as an attract...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
MDPI
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470194/ |